Circulation Journal
Official Journal of the Japanese Circulation Society
http://www.j-circ.or.jp

REVIEW

The Quest for the Adult Cardiac Stem Cell

Michela Noseda, MD, PhD; Marta Abreu-Paiva, PhD; Michael D. Schneider, MD

Over the past 2 decades, cardiac regeneration has evolved from an exotic fringe of cardiovascular biology to the forefront of molecular, genetic, epigenetic, translational, and clinical investigations. The unmet patient need is the paucity of self-repair following infarction. Robust regeneration seen in models such as zebrafish and newborn mice has inspired the field, along with encouragement from modern methods that make even low levels of restorative growth discernible, changing the scientific and technical landscape for effective counter-measures. Approaches under study to augment cardiac repair complement each other, and encompass grafting cells of diverse kinds, restarting the cell cycle in post-mitotic ventricular myocytes, reprogramming non-myocytes, and exploiting the dormant progenitor/stem cells that lurk within the adult heart. The latter are the emphasis of the present review. Cardiac-resident stem cells (CSC) can be harvested from heart tissue, expanded, and delivered to the myocardium as a therapeutic product, whose benefits may be hoped to surpass those achieved in human trials of bone marrow. However, important questions are prompted by such cells' discovery. How do they benefit recipient hearts? Do they contribute, measurably, as an endogenous population, to self-repair? Even if "no," might CSCs be targets for activation in situ by growth factors and other developmental catalysts? And, what combination of distinguishing markers best demarcates the cells with robust clonal growth and cardiogenic potential? (*Circ J* 2015; **79:** 1422–1430)

Key Words: Cardiac regeneration; Heart repair; Platelet-derived growth factor receptor-*α*; Stem cells

Cardiac Regeneration: Filling a Therapeutic Void

Heart disease has emerged as an auspicious target for regenerative medicine,[1–6] because of the sheer scope of the healthcare burden. Cardiovascular disorders are a paramount cause of death and disability, among which ischemic heart disease caused 13% of global mortality, or >7 million deaths worldwide in 2012.[7] Over the past 30 years, progress in treating ischemic heart disease has improved patient outcomes, reducing the early mortality from myocardial infarction. Yet, despite success in acutely restoring myocardial blood flow, the remaining cardiac damage predisposes to later heart failure.[8] This inexorable cause-effect relationship contributes to the mounting prevalence of heart failure, predicted to increase 50% within 15 years.[8–11] Hence, it may be imperative not merely to achieve timely reperfusion, the clinical state of the art, but also to reverse the existing tissue damage, to prevent the progressive dysfunction that follows.

In stark contrast, regeneration of the heart is robust in species such as the axolotl, newt, and zebrafish,[12–15] in which total limb regeneration even occurs. How the heart reconstitutes itself in these circumstances, at the cellular level, was long ambiguous, but recent evidence indicates that zebrafish generate new cardiomyocytes by proliferation of pre-existing ones as their basis for scarless healing. This Promethean ability is also found, albeit transiently, in mice after birth,[16,17] where it is contingent on neonatal macrophages[18] and the *Hippo* effector *Yap*.[19]

Whether substantial cardiac regeneration might also exist in adult mammals, and by what means if so, has been more contentious. A pulse-chase analysis of ^{14}C incorporated into cardiac DNA during the mid-century decades of atmospheric atom bomb testing confirmed that human cardiomyocytes renew themselves, albeit at the low rate of 1% per year in young adults and just 0.45% per year in the elderly.[20] Claims of much more extensive myocyte cycling have been retracted.[21] Analogous studies of adult mice, by stable isotope labeling and multi-isotope imaging mass spectrometry, confirmed cardiomyocyte renewal through the division of pre-existing cardiomyocytes.[22] Cardiomyocytes in young adults were labeled by [^{15}N]thymidine at an annual rate of 5.5%, most of which was polyploidization. Mononucleated [^{15}N]$^{+}$ myocytes also were detected (annual rate, 0.76%), more indicative of cell division. Conversely, studies using flow cytometry of isolated myocyte nuclei[23] and transgenic fluorescent anillin to mark cytokinesis[24] challenge the conclusions that measurable myocyte turnover occurs in the adult mouse heart and that repopulation occurs via pre-existing myocytes.

What is the alternative to this seeming impasse? Fate-mapping using the Cre/lox system provides a means to indelibly tag cells in model organisms, based on a gene's expression in a chosen cell type, at a chosen time, and suggests that the adult mammalian heart regenerates itself via the lineage decisions of resident progenitor/stem cells.[25–27] The constellation of

Received May 26, 2015; accepted May 27, 2015; released online June 12, 2015
National Heart and Lung Institute, Imperial College London, London, UK
Mailing address: Michela Noseda, MD, PhD or Michael D. Schneider, MD, National Heart and Lung Institute, Imperial College London, ICTEM 336, Du Cane Road, London W12 0NN, UK. E-mail: m.noseda@imperial.ac.uk or m.d.schneider@imperial.ac.uk
ISSN-1346-9843 doi:10.1253/circj.CJ-15-0557
All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp

relevant markers to demarcate the cells in question is introduced next, with details of these fate-mapping studies subsequently.

Signatures of the Cardiac Stem Cell (CSC)

A longish list of potential identifiers has accumulated, over the past 12 years, to describe, define, isolate, and purify the formerly unsuspected adult CSC.[1,5] What criteria are necessary and sufficient for "stemness", and what tests provide reliable proof? Stem cells reproduce themselves (are self-renewing) and give rise to differentiated cells. Growth potential is commonly assessed as the ability to form colonies derived from single cells (clones) and capable of long-term propagation. Surprisingly, few studies have assessed the cloning efficiency of freshly isolated cardiac cells, most relying on prior adaptation to cell culture to evoke clonability. Equally, little work has systematically compared the molecular profiles of cloned cells vs. the fresh starting cells, or investigated clonal variation and its basis. The value of clonal analysis is highlighted by the inherent inability of purified cells to prove multilineage potential: no matter how purified, the population might harbor an indeterminate variety of progenitor cell types. Ultimately, measuring cells' plasticity (1 type of differentiated progeny, 2, 3, many, or all?) can only be resolved using offspring expanded from a single starting cell.

Through the combination of single-cell expression profiling and rigorous clonal analysis, we unmasked several aspects of the complex inter-relationships among the reported cardiac progenitor cell (CPC)/CSC, suggesting a multiparameter strategy for their phenotypic and functional identification, not reliance on a single determinant alone[28] (**Figure**). Early on, we used the orphan receptor stem cell antigen 1 (Sca1) as a surface marker to identify adult cardiac-resident cells having the capacity to differentiate into cardiomyocytes from an immature undifferentiated state when delivered to the infarcted mouse heart.[29] The logic of testing Sca1 was its known essential role in both hematopoietic stem cells and mesenchymal stem cells (MSCs), revealed by gene ablation in mice.[30] Its ligand remains unknown. Independent studies confirmed the capacity of cardiac Sca1$^+$ cells to undergo cardiomyocyte differentiation, in the setting of cell grafting, and as an endogenous population tracked by lineage-tracing tools.[26,27,31–34] Fewer investigations have scrutinized the vascular contribution of Sca1$^+$ CPCs. Interestingly, their differentiation into endothelium is impaired by cardiomyocyte-specific deletion of STAT3 or the cardiotoxic anticancer drug doxorubicin, attributable to deficient erythropoietin production by heart failure-prone cardiomyocytes.[35]

Sca1 is reportedly co-expressed by the CPCs denoted by other markers, including the hematopoietic growth factor receptor c-kit,[33,36,37] and may even be essential for the function of c-kit$^+$ CSCs.[33] The Sca1$^+$ population comprises a large fraction of adult cardiac non-myocytes; hence, inherently, additional markers were likely needed to best pinpoint the clone-forming cardiogenic cells. The anticipated utility of other markers was also foreseen, given that the Sca1 gene, *Ly6a*, has no counterpart in species other than the mouse.

In bone marrow, a "side population (SP)" phenotype based on expelling Hoechst dye 33342 identifies hematopoietic stem cells with long-term repopulating capacity.[38,39] Analogous dye-extruding SP cells are enriched 100-fold in the cardiac Sca1$^+$ population relative to cardiac non-myocytes as a whole, and showed potential for differentiation in vitro and in vivo into the endothelial, smooth muscle and cardiomyocyte lineages.[28,29,31,40–42] Cardiac SP cells also differentiate into non-cardiac mesodermal derivatives (adipocytes, osteocytes), suggesting a MSC-like phenotype.[42] Only CD31$^-$ cardiac SP cells had cardiomyogenic potential.[41] However, the range of potency must be assessed at a clonal level, and these early studies did not determine whether a single cardiac SP cell has multilineage capacity.

Sca1 is also expressed in a subset of murine cardiosphere-derived cells, which are obtained via non-adherent growth, are intentionally heterogeneous, and have well-demonstrated heart repair potential.[43] Sca1$^+$ CSC/CPC, as well as the more diverse cardiospheres, express several diagnostic MSC markers.[28,31,44–46] Functional MSC-like cells (cardiac colony-forming units, fibroblast: cCFU-F) have been identified in the adult heart, with individual colonies showing cardiovascular tri-lineage differentiation capacity.[45] More rarely, colonies had trans-germ layer capacity, giving rise to endodermal (hepatocyte) and neurectodermal (neuron, glia, oligondrocyte) fates. cCFU-Fs are especially enriched within the platelet-derived growth factor receptor (PDGFR)α^+ subset of cardiac Sca1$^+$ cells.[45]

Mesoangioblasts are vessel-derived progenitor cells from the aorta and solid organs, including the heart, that typically express MSC markers, c-kit, and Sca1,[47,48] which drive heart repair in part via secreted proteins' promoting host myocyte survival: fibroblast growth factor (FGF)-2, hepatocyte growth factor (HGF), and insulin-like growth factor (IGF)-1.[49] Pericytes derive from the microvasculature, possess many overlapping properties (CD44, CD146, CD13, CD49b and Sca-1) but not the endothelial lineage marker Flk-1,[50] make direct and indirect contributions to angiogenesis, and exert paracrine effects on host myocyte proliferation and resident CSCs.[51]

By contrast to these stem cell-associated criteria (surface markers, dye expulsion, growth properties), others have identified CPCs based on reporter genes for embryonic heart transcription factors such as *Isl1* or *Wt1*. *Isl1* is a well-established marker of multipotent CSCs during embryogenesis and in differentiating embryonic stem cells (ESCs),[52] but its relevance to adult cardiac plasticity is unproven. *Wt1* is expressed in embryonic epicardium, including the pro-epicardial organ that generates the blood vessels and stroma of the heart. *Wt1* is reactivated after myocardial infarction and augmented by thymosin β4, a peptide that promotes heart repair by epicardium-derived cells through mechanisms including vascular and cardiomyocyte differentiation.[53,54] Activated adult Wt1$^+$ cells are c-kit$^-$ but 80% Sca1$^+$.[54]

Sca1 at the Crossroads of CSC Markers

These and other investigations suggest that Sca1 might overlap in mice with most if not all reported criteria that denote the adult CPC/CSC. Despite this, a finer and more exact definition was required to pinpoint the cells of greatest clonal growth capacity, ascertain their differentiation potential as single-cell progeny, compare the molecular signature of cloned populations with the native starting cells, and clarify the 2- and 3-way relationships among the seemingly diverse progenitors sharing Sca1 expression as a feature in common.

One attempt to compare the molecular signature of CPCs was performed on cardiac c-kit$^+$, Sca1$^+$ and SP cells by microarray-based transcriptome analysis.[55] Sca1$^+$ as well as SP cells were found to be enriched for 2 cardiogenic transcritpion factors[56] (*Mef2c* and *Hand2*), suggesting they might have a committed cardiac lineage potential, as previously found.[29,41] Cardiac Sca1$^+$ and SP cells are more closely related to cardiomyocytes by hierarchical clustering than are c-kit$^+$ cells, which correlate



Figure. Platelet-derived growth factor receptor (PDGFR)*α* demarcates the clonogenic cardiogenic Sca1+ cell. (**Upper**) Hematopoietic lineage (Lin) negative non-myocytes from dissociated adult mouse myocardium purified by flow-sorting based on Sca1 expression, Hoechst dye efflux, and reciprocal expression of PDGFR*α* vs. CD31. (**Middle**) Regardless of their side population (SP) phenotype, PDGFR*α*+ cells expressed a cardiogenic gene signature (representative single-cell qRT-PCR results are shown), arose from ancestors expressing cardiac transcription factors, and were highly clonogenic. Sectors 1–4 from the flow cytometry results are mapped to the corresponding regions of the Venn diagram. (**Lower left**) Donor-derived cardiomyocyte 12 weeks after stem cell grafting. Single-cell progeny from the illustrated clone also demonstrated vascular smooth muscle and endothelial differentiation and incorporation into vascular structures. (**Lower right**) Grafted cardiac stem cells reduce adverse remodeling. End-systolic images are shown by 9.4 Tesla magnetic resonance tomography. MI, myocardial infarction. Adapted from Noseda M, et al.[28]

least with cardiomyocytes and other CSCs, perhaps indicating a more primitive population.[55] These findings are consistent with the presence by qRT-PCR of *Hand2*, *Mef2c*, and most other essential cardiogenic transcription factors in the Sca1+ population.[29] In contrast, relative to bone marrow cells, cCFU-Fs lack enrichment for cardiogenic transcription factors excepting *Mef2c*.[45,46] Differences between studies may be related to the cell isolation methods, which might either select or provoke distinguishable phenoptypes, the techniques used to profile gene and protein expression, or dilutional effects in mixed populations.

The intricate relationship among CPCs having Sca1 in

common was clarified using multiparametric flow cytometry, single-cell qRT-PCR, cell cloning by single-cell deposition, and a detailed analysis of clonal progeny, revealing subsets of cells and microheterogeneities that were previously obscured.[28] We undertook a multistep approach to enrich for defined subsets of interest (**Figure**). In this way, it was possible to identify cardiac Lin⁻ Sca1⁺ SP cells that co-express PDGFRα as unprecedentedly clonogenic (efficiency, 30%). Their cloned progeny faithfully retain the molecular signature of fresh cells and have tri-lineage potential for the major differentiated cell types of the heart after grafting. Our findings reconcile many prior reports on the adult CSC and are summarized as an explanatory Venn diagram (**Figure**).

Under our current conditions, Sca1 is detected in nearly one-third of the hematopoietic lineage-negative, cardiomyocyte-depleted, stromal fraction of the adult mouse heart. Size alone suggests that Sca1 encompasses a heterogeneous pool of cardiac cells, as further shown by flow cytometry even in the earliest reports.[29] Indeed, Lin⁻ Sca1⁺ cells can be fractionated into 2 subpopulations that largely are non-overlapping and mutually exclusive: PDGFRα^+/CD31⁻ and PDGFRα^-/CD31⁺ cells, the latter being roughly 4-fold more numerous. At the other extreme of abundance, SP cells when gated stringently represent 1–3% of the overall Sca1⁺ cells, likewise existing as dichotomous PDGFRα^+/CD31⁻ and PDGFRα^-/CD31⁺ forms.[28,29,41,42] Compared with the "main" population (Non-SP) cells, SP cells are enriched 4-fold for PDGFRα^+.[28] Notably, PDGFRα is a key marker of cardiac specification in ESCs and flow-sorted cells from E7–7.5 embryos.[57,58]

Single-Cell Gene Expression Profiles

By qRT-PCR for a panel of 45 genes in freshly isolated single cells, the phenotypic dichotomy defined by PDGFRα and CD31 in the broad Sca1⁺ population and among Sca1⁺ SP cells correlates precisely with a sharp partition in the molecular signature.[28] Cells expressing PDGFRα are enriched for *Pdgfra* mRNA, pluripotency markers (*Nanog*, *Oct4*, *Klf4*), and genes encoding essential cardiogenic transcription factors (*Gata4/6*, *Tbx5/20*, *Hand2*, *Mef2a/c*) but not sarcomeric genes. Because several other cardiac transcription factors are silent (*Isl1*, *Nkx2–5*), the cells resemble an incomplete form (*forme fruste*) of the multipotent CSC during embryogenesis[56] or pluripotent cells' differentiation to a cardiac fate.[59] These PDGFRα^+ cells are largely negative for endothelial lineage markers (*Flk1*, *Cdh5*, *Vwf*). Conversely, Sca1⁺ cells lacking *Pdgfra*/PDGFRα, but expressing CD31, do not express *Gata*, *Tbx* and *Hand* genes, being enriched for endothelial lineage markers instead.[28]

This dichotomous signature immediately suggests a mechanistic basis for the divergent cardiogenic potential reported for CD31⁻ and CD31⁺ SP cells.[41] Indeed, dissecting the Sca1⁺ cells into 4 populations (combining Hoechst 33342, PDGFRα, and CD31), the expression profile of incomplete cardiac mesoderm segregates precisely with PDGFRα, independently of SP status.[28]

As mentioned, this Sca1⁺ PDGFRα^+ consensus signature encompasses many cardiac transcription factors that are essential for cardiogenesis during development.[56] However, single-cell profiling revealed that individual fresh cells express, chiefly, just 2 or 3 of the core factors *Gata4*, *Hand2*, *Mef2c*, and *Tbx5*, in various combinations.[28] This level of microheterogeneity was previously unknown, and the mosaic phenotype of fresh cells was recapitulated in their clonal progeny. For a discussion of molecular mechanisms that might underlie mosaic gene expression see Suter et al[60] and Chang et al.[61] When forcibly expressed, none of the single factors *GATA4*, *MEF2C*, or *TBX5* was sufficient to trigger the cells' differentiation program, whereas cardiac gene and protein expression was provoked by *TBX5* in concert with *MYOCD* – a co-activator missing from the cells at baseline.[62]

Stratifying Clonal Growth

The initially reported clonogenic potential of cardiac Sca1⁺ cells was as 0.1%, and long-term expandable cells just 0.03%,[63] consistent with several explanations, including innately poor growth potential, inadequate culture conditions, and heterogeneity of the cells tested. Most prior attempts to show clonal growth of CSCs with other markers, including c-kit and the SP phenotype, relied on pre-adaptation of cells in culture, feeder layers, limiting dilution, or colony formation,[31,45,64] rather than cloning fresh single cells deposited by flow-sorting. Under the latter conditions, each droplet is individually and unambiguously interrogated, to ensure it does not contain a doublet or aggregate.

Based on preparative cell sorting with various combinations of the discussed identifiers, single cells were deposited in 96-well plates to assess the subpopulations' clonal growth, self-renewal, and multilineage potential.[28] SP status was a potent predictor of clonal growth under these exacting conditions, as seen earlier by colony formation in methylcellulose.[41] However, the SP phenotype was dispensible: PDGFRα^+ Non-SP cells were clonogenic (2% efficiency in physiological hypoxia), yet the combined PDGFRα^+ SP phenotype was highly synergistic (cloning efficiency >25%).[28] Cells lacking PDGFRα but expressing CD31 were rarely if ever clonable under our conditions, even if positive for the SP phenotype. Cloned Sca1⁺ SP cells could be propagated for over 1 year, retained the cognate features (Sca1, SP status), maintained the cardiogenic gene signature, and were enriched for generating secondary clones, features together indicating self-renewal.[28]

ATP-binding cassette transporters that mediate the SP dye-efflux phenotype include Abcg2 and Mdr1. Both were expressed at equal levels in SP and Non-SP cells, suggesting that differences in pump activity, not expression, might distinguish the 2 states.[28]

Lineage Potential and Cell Therapy

We emphasize the importance of our clonogenicity data, not merely as a metric of "stemness", but more importantly as a tool to assess multilineage differentiation in the progeny of single cells. All the clones of Sca1⁺ SP cells tested expressed *Pdgfra* mRNA and PDGFRα.[28] Within 2 weeks of cardiac grafting, molecular markers of tri-lineage potential emerged (cardiac troponin I, myosin light chain 2v, sarcomeric α-actin, sarcomeric myosin heavy chain, CD31, von Willebrand factor, smooth muscle myosin heavy chain). At 12 weeks, donor-derived differentiating cells were incorporated into the endothelial and smooth muscle layers of blood vessels, and, if cardiac, were typically rod-shaped, bi-nucleated, and striated (**Figure**). Thus, single-cell derivatives have tri-lineage capacity and can override the "developmental arrest" of a mosaic, incomplete cardiogenic program.

As in related studies using other defined cells or cardiospheres,[31,65–69] grafted cells retained for 3 months were vanishingly rare. Nonetheless, serial magnetic resonance imaging (MRI) demonstrated that cloned Sca1⁺ SP cells delivered to myocardium at the time of infarction successfully reduced infarct size, increased left ventricular ejection fraction, and reduced adverse remodeling.[28] This recurring combination of

Table. Clinical Trials of Cardiac Repair With Heart-Derived Progenitor/Stem Cells

Study	CADUCEUS (CArdiosphere-Derived aUtologous stem CElls to reverse ventricULar dySfunction)	SCIPIO (Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy)	TICAP (Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology)	ALCADIA (AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy)
Clinicaltrials.gov identifier	NCT00893360	NCT00474461	NCT01273857	NCT00981006
Country	USA	USA	Japan	Japan
Principal investigator	Eduardo Marban, Cedars-Sinai Medical Center	Roberto Bolli, University of Louisville	Hidemasa Oh, Okayama University	Hiroaki Matsubara, Kyoto Prefectural University of Medicine
Type	Phase I	Phase I	Phase I	Phase I
Status	Completed, results reported	Completed, results reported	Completed, results reported	Completed, preliminary results reported
References	Makkar et al[91] Malliaris et al[92]	Bolli et al[93] Chugh et al[94]	Ishigami et al[95]	Takahara et al[96] (abstract)
Diagnosis	Ischemic LV dysfunction/ recent MI	Coronary artery disease/ CHF/ICM	HLHS, single ventricle, heart failure	CHF, ICM, ventricular dysfunction
Enrollment	31	33	14	6
Age, sex	18–80 years, both sexes	18–75 years, both sexes	≤6 years, both sexes	20–80 years, both sexes
Cell type	Autologous cardiosphere-derived cells from RV endocardial biopsy	Autologous c-kit$^+$ cardiac stem cells from RAA (magnetic sorting)	Autologous atrial cardiosphere-derived stem cells	Autologous human CD105$^+$/CD90$^+$ cardiosphere-derived cells, enriched for ESC markers and mesenchymal features
Intervention route	Intracoronary	Intracoronary	Intracoronary	Transepicardial, in and around scar at time of CABG
Dose	12.5 or 25×10^6 cells within 36 days of sampling; 3 injections lasting 15 min	1×10^6 cells 4 months after harvest; 4 injections lasting 3 min	0.3×10^6 cells/kg; up to 3 vessels; 1 month after Norwood-Glenn, Glenn, or Fontan procedure	0.5×10^6 cells/kg (20 sites), overlaid by gelatin hydrogel sheet containing 200 μg bFGF
Inclusion criteria				
NYHA class	1–2	2.1	NYUPHI 10	3.8 (mean)
LVEF	25–45%	<40%	Not applicable	15–35%
Results				
NYHA class improvement	No	Yes	Yes (NYUPHI 6.1 at 18 months)	Yes
LVEF improvement	Improved regional function but not LVEF at 1 year	13.7% at 1 year	9% at 18 months (RVEF)	12.1% at 6 months
Scar reduction	11% at 1 year	30% at 1 year	Not applicable	4% at 6 months

*Hidemasa Oh, personal communication. bFGF, basic fibroblast growth factor (FGF-2); CABG, coronary artery bypass graft; CHF, congestive heart failure; DCM, dilated cardiomyopathy; EF, ejection fraction; HLHS, hypoplastic left heart syndrome; ICM, ischemic cardiomyopathy; LV, left ventricle; MI, myocardial infarction; NYHA, New York Heart Association; NYUPHI, New York University Pediatric Heart Failure Index; RAA, right atrial appendage; RV, right ventricle.

(Table continued the next page.)

marked functional improvement despite meager cell retention plausibly suggests that, under the present conditions of cell delivery, a paracrine mechanism of benefit predominates.[31,65–69] Paracrine effects of clonally expanded Sca1$^+$ cells on cardiomyocyte survival and angiogenesis are attributable in part to soluble VCAM-1 and soluble junctional adhesion molecule-A.[31,70] Related effector mechanisms of grafted heart-derived cells include enhancing cardiomyocyte proliferation and activating host CSCs, via HGF, IGF-I, stromal cell-derived factor-1, angiopoietin-2, vascular endothelial growth factor,[66,68,71,72] and exosomes,[73–75] secreted extracellular vesicles containing microRNAs that regulate the recipient tissue. Suppressing Sca1 (*Ly6a*) by RNA interference downregulates HGF and the benefits of cell transplantation on angiogenesis and myocyte survival.[63] The functional superiority of expanded cardiac Sca1$^+$ cells and cardiosphere-derived cells over bone marrow and non-cardiac MSCs in side-by-side comparisons of heart repair is at present ascribed to their paracrine potency.[66,70] Such findings are of heightened interest, given the failure of promising bone marrow trials in the most authoritative meta-analysis.[76] The benefits of c-kit$^+$ GATA^{high} CSCs on cardiomyocyte survival are negated by blocking IGF-I;[72] however, depleting c-kit$^+$ cells from cardiospheres has no effect on the observed improvements.[44]

In light of this emerging consensus, paracrine effects plausibly dominate not just in experimental studies delivering CSCs, but also in the emerging human trials (Table). Whereas an empirical case exists that mixed cell populations might be better therapeutically than homogeneous ones,[77–79] defining each component and its precise contribution may lead best to therapies that are stem cell-inspired yet ultimately cell-free. The greater extent of cardiomyocyte formation by heart-derived cells than other adult stem cells could matter more, once engraftment is durable. This prediction may require a tissue engineering solution,[80,81] not just the right cell, and remains to be tested directly.

Study	PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease)	ALLSTAR (Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration)	DYNAMIC (Dilated cardiomYopathy iNtervention With Allogeneic Myocardlally-regenerative Cells)
Clinicaltrials.gov identifier	NCT01829750	NCT01458405	NCT02293603
Country	Japan	USA	USA
Principal investigator	Hidemasa Oh, Okayama University	Andrew Hamer, Capricor	Rajendra Makkar, Cedars-Sinai Heart Institute; Andrew Hamer, Capricor
Type	Phase II	Phase I and II	Phase I
Status	On-going	On-going	On-going
References	Not applicable	Not applicable	Not applicable
Diagnosis	HLHS, single RV, single LV	MI	DCM, ICM, non-ischemic cardiomyopathy, CHF
Enrollment	34	274	42
Age, sex	≤20 years, both sexes	≥18 years, both sexes	≥18 years, both sexes
Cell type	Autologous atrial cardiosphere-derived stem cells	Allogeneic cardiosphere-derived cells CAP-1002 (from whole hearts)	Allogeneic cardiosphere-derived cells CAP-1002
Intervention route	Intracoronary	Intracoronary	Sequential intracoronary infusion in up to 3 coronary arteries supplying 3 major cardiac territories
Dose	0.3×10^6 cells/kg; 1 month after Norwood-Glenn, Glenn, or Fontan procedure	25×10^6 cells; single dose by intracoronary infusion	Phase Ia: stepwise dose escalation; up to 3 coronary arteries supplying 3 major heart territories
Inclusion criteria			
NYHA class	NYUPHFI 13–15*	≤3	3 or ambulatory 4
LVEF	<60%	≤45%	<35%
Results			
NYHA class improvement	Not available	Not available	Not available
LVEF improvement	Not available	Not available	Not available
Scar reduction	Not available	Not available	Not available

Insights From Cell Origins

The developmental origin of adult CPCs has only recently received close study, confounding factors being the multitude of cells described and lack of an agreed marker. Among the a priori possibilities, cardiac-resident stem cells might arise as a dedifferentiated product of "lapsed" cardiomyocytes, a trans-differentiated product of bone marrow cells in the cardiac milieu, a derivative of migratory neural crest cells, offspring of the hemangioblast, or an undifferentiated remnant of the first or second heart field during embryogenesis. In our dissection of the cardiac Sca1$^+$ population, nearly all cells were fated by the primitive mesodermal transcription factor *Mesp1*, regardless of their SP status or PDGFRα Expression.[28] Little or no contribution was seen from committed hematopoietic cells (*Vav-Cre*), neural crest (*Wnt1-Cre*), or preformed cardiomyocytes (*Myh6-Cre*).

Intermediate levels of recombination were seen with tracers of mesoderm patterning and commitment to a cardiovascular fate.[28] Regardless of SP status, PDGFRα^+ and PDGFRα^- cells were partially derived from ancestors expressing *Nkx2–5* and *Isl1*, cardiogenic genes that are silent in these adult cells but demarcate bipotent and multipotent embryonic populations that form the heart and are indispensable for normal cardiogenesis.[82,83] Large differences between PDGFRα^+ and PDGFRα^- cells were found using markers of epicardial and vessel-associated origins: PDGFRα^+/CD31$^-$ cells were preferentially fated by the embryonic epicardial genes *Wt1* and *cGATA5*, whereas PDGFRα^-/CD31$^+$ cells arose chiefly from precursors expressing *Flk1* and *Tie2*.[28]

Does this possible signify a dual origin for Sca1$^+$ cells? With cardiospheres, using *Myh6-MerCreMer*×Z/EG mice, dedifferentiation of cardiomyocytes was noted as a source for a subset of the cells.[84] But, cardiospheres by design are heterogeneous, and more than 1 source is expected in this instance. A more parsimonious explanation for the fate map of PDGFRα^+ cells may be the contribution of *Nkx2–5* and *Isl1* to the pro-epicardial organ, source of the epicardium, coronary vessels, and most cardiac interstitial cells, epicardially-derived cells being a potential reservoir of cardiac progenitors.[54,80] A largely congruent fate map was proposed for the cCFU-F, which as mentioned expresses PDGFRα and Sca1, but not most cardiogenic genes, and may be a precursor or more primitive form of the cells we studied.[45] It is unknown whether

Nkx2–5- and *Wt1*-fated cells differ in molecular or functional terms.

In summary, given the heterogeneity of cardiac Sca1 cells and the complex potential origins, we sought to study the inception of specific subsets, based on combinatorial use of multiple identifiers. Partitioning 4 Sca1$^+$ populations (ie, SP/PDGFRα^+, SP/CD31$^+$, Non-SP/PDGFRα^+ and Non-SP/CD31$^+$) allowed us to identify a shared developmental pathway that bifurcates to form PDGFRα^+ cells vs. CD31$^+$ ones, associated, respectively, with cardiogenic vs. vasculogenic genes.

PDGFRα^+ cells exist in human hearts, whose developmental and reparative potential is beginning to be investigated.[84,85] No significant cardiogenic differentiation was observed in PDGFRα^+ human fetal heart cells treated as monolayers with 5'-azacytidine or as embryoid body-like aggregates with the cardiogenic growth factors activin A and bone morphogenetic protein-4.[84] Conversely, cardiac differentiation and angiogenic responses were demonstrated in PDGFRα^+ human myocardial pericytes, purified using CD146 and expressing other pericyte markers (NG2, PDGFRβ).[85] Thus, the potential utility of PDGFRα^+ human cardiac cells warrants further study.

Endogenous CSCs and Self-Repair

What about differentiation by native cells, in situ? Lineage-tracing experiments mapped the progeny of cardiac Sca1$^+$ cells by multi-color Cre tagging (*Sca1-tTA/LC1-Cre/R26R-Confetti*),[26] in which single cells stochatically undergo distinct recombination events and express 1 of 4 distinct fluorescent colors.[86] Sca1-fated cells infrequently displayed multilineage cardiovascular potential, suggesting that any multipotent Sca1 population is rare.[26] Roughly 4% of Sca1-fated cells were cardiomyocytes at 2–12 months of age, one-third of which were generated after birth.[26] Myocardial infarction elicited no change, but Sca1-derived cardiomyocytes increased 3-fold during pressure-overload hypertrophy.[26]

Analogously, cardiomyocytes were reportedly regenerated from existing cardiac-resident c-kit$^+$ cells using lentiviral delivery of Cre driven by a *c-kit* promoter and high-dose isoproterenol, a model of diffuse myocardial damage resembling takotsubo cardiomyopathy.[37] Those findings have been emphatically challenged by discordant results using tamoxiphen-dependent Cre targeted to the native *c-kit* locus: generating endothelial cells was the predominant effect.[87] Ordinarily, a "knock-in" offers the greatest fidelity of gene expression and would logically be given the benefit of doubt here. Countervailing arguments that have been raised include theoretical concerns that *c-kit-Cre* knock-in mice were defective for regeneration (because of *c-kit* haploinsufficiency), or might fail to capture as many c-kit-fated cells in the heart (because of lesser expression than with viral delivery).[88]

Rather than emphasize this ensuing technical debate, we wish to emphasize a conceptual difference among the various fate-mapping studies. Even if little or no myocyte creation occurs via a given cell type, under unassisted conditions, we view the relevant translational question as whether myocyte creation by that route can be enhanced, experimentally. (In much the same way, transdifferentiation of fibroblasts to cardiomyocytes is rightfully pursued, without being known to occur spontaneously.) At least 4 interventions enhance cardiomyocyte formation from a non-myocyte precursor. Grafting bone marrow or cardiospheres augments new myocyte creation by non-myocytes within the heart.[69,89] Treatment with thymosin β4 is essential for cardiac myogenesis by Wt1$^+$ cells, following infarction.[54] Of most direct relevance to our laboratory's studies, cardiomyocyte formation by the native Sca1$^+$ population appears responsible for the regenerative effect of prostaglandin E2 (PGE2) in mice.[27] In those experiments, cardiomyocyte replacement in the border zone by progenitor cells was blocked by cyclooxygenase (COX) inhibitors (indomethacin, celecoxib), increased by PGE2, and required the EP2 receptor.[27] Although it is uncertain if this action is entirely cell-autonomous, or involves known effects of PGE2 on the inflammatory milieu, direct effects were demonstrated in culture, with induction of Nkx2–5 and cardiac troponin T.[27]

In short, despite differences in the cells and models used, current data point to the existence of a cardiac regenerative capacity, albeit meager if unassisted. Thus, the possibility of activating endogenous progenitor cells in situ to regenerate viable and functional myocardium is an attractive therapeutic option, distinct from CSCs' utility as a cell therapy product. There are precedents for more than 1 population being led to a given cell fate; indeed, fate-mapping studies of brown adipogenesis implicate both Sca1$^+$ PDGFRα^+ stromal cells and pre-existing white adipocytes.[90] Hence, whether endogenous PDGFRα^+ precursors generate new cardiomyocytes merits investigation, and it may be more straightforward to interpret than the Sca1 fate map, given PDGFRα^+ cells' greater homogeneity.

Acknowledgments

This study was supported by the British Heart Foundation (BHF; CH/08/002, RE/13/4/30184, RG/08/007, RG/15/1/31165, RM/13/1/30157, SI/11/2/28875), European Commission (CardioCell, 223372), European Research Council (233158), and a Medical Research Council-BHF Cardiovascular Stem Cell Research Strategic Development Grant (G0901467).

Competing Financial Interests

Research funding: British Heart Foundation, Wellcome Trust (MDS). Travel expenses, gifts and other contributions: Japanese Circulation Society, Sanford Burnham Medical Research Institute (MDS).

Grants

British Heart Foundation (BHF; CH/08/002, RE/08/002, RE/13/4/30184, RG/08/007, RG/15/1/31165, RM/13/1/30157, SI/11/2/28875), European Commission (223372), European Research Council (233158), and a Medical Research Council-BHF Cardiovascular Stem Cell Research Strategic Development Grant (G0901467).

References

1. Mercola M, Ruiz-Lozano P, Schneider MD. Cardiac muscle regeneration: Lessons from development. *Genes Dev* 2011; **25:** 299–309.
2. Lin Z, Pu WT. Strategies for cardiac regeneration and repair. *Sci Transl Med* 2014; **6:** 239rv1.
3. Gerbin KA, Murry CE. The winding road to regenerating the human heart. *Cardiovasc Pathol* 2015; **24:** 133–140.
4. van Berlo JH, Molkentin JD. An emerging consensus on cardiac regeneration. *Nat Med* 2014; **20:** 1386–1393.
5. Chong JJ, Forte E, Harvey RP. Developmental origins and lineage descendants of endogenous adult cardiac progenitor cells. *Stem Cell Res* 2014; **13:** 592–614.
6. Fox IJ, Daley GQ, Goldman SA, Huard J, Kamp TJ, Trucco M. Stem cell therapy: Use of differentiated pluripotent stem cells as replacement therapy for treating disease. *Science* 2014; **345:** 1247391.
7. World Health Organization. Global health estimates: Deaths by cause, age, sex and country, 2000–2012. Geneva: WHO, 2014.
8. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, et al. Long-term trends in the incidence of heart failure after myocardial infarction. *Circulation* 2008; **118:** 2057–2062.
9. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: The Global Burden of Disease 2010 study. *Circulation* 2014; **129:** 1483–1492.
10. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ,

Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014; **63:** 1123–1133.
11. Vigen R, Maddox TM, Allen LA. Aging of the United States population: Impact on heart failure. *Curr Heart Fail Rep* 2012; **9:** 369–374.
12. Cano-Martinez A, Vargas-Gonzalez A, Guarner-Lans V, Prado-Zayago E, Leon-Oleda M, Nieto-Lima B. Functional and structural regeneration in the axolotl heart (Ambystoma mexicanum) after partial ventricular amputation. *Arch Cardiol Mex* 2010; **80:** 79–86.
13. Forbes SJ, Rosenthal N. Preparing the ground for tissue regeneration: From mechanism to therapy. *Nat Med* 2014; **20:** 857–869.
14. Kikuchi K, Poss KD. Cardiac regenerative capacity and mechanisms. *Annu Rev Cell Dev Biol* 2012; **28:** 719–741.
15. Wang J, Cao J, Dickson AL, Poss KD. Epicardial regeneration is guided by cardiac outflow tract and Hedgehog signalling. *Nature* 2015 May 4, doi:10.1038/nature14325.
16. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, et al. Transient regenerative potential of the neonatal mouse heart. *Science* 2011; **331:** 1078–1080.
17. Porrello ER, Olson EN. A neonatal blueprint for cardiac regeneration. *Stem Cell Res* 2014; **13:** 556–570.
18. Aurora AB, Porrello ER, Tan W, Mahmoud AI, Hill JA, Bassel-Duby R, et al. Macrophages are required for neonatal heart regeneration. *J Clin Invest* 2014; **124:** 1382–1392.
19. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, et al. Hippo pathway effector Yap promotes cardiac regeneration. *Proc Natl Acad Sci USA* 2013; **110:** 13839–13844.
20. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. *Science* 2009; **324:** 98–102.
21. Kajstura J, Rota M, Cappetta D, Ogorek B, Arranto C, Bai Y, et al. Cardiomyogenesis in the aging and failing human heart. *Circulation* 2012; **126:** 1869–1881 (Notice of retraction, *Circulation* 2014; **129:** e1466).
22. Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, et al. Mammalian heart renewal by pre-existing cardiomyocytes. *Nature* 2013; **493:** 433–436.
23. Walsh S, Ponten A, Fleischmann BK, Jovinge S. Cardiomyocyte cell cycle control and growth estimation in vivo: An analysis based on cardiomyocyte nuclei. *Cardiovasc Res* 2010; **86:** 365–373.
24. Hesse M, Raulf A, Pilz GA, Haberlandt C, Klein AM, Jabs R, et al. Direct visualization of cell division using high-resolution imaging of M-phase of the cell cycle. *Nat Commun* 2012; **3:** 1076.
25. Hsieh PC, Segers VF, Davis ME, MacGillivray C, Gannon J, Molkentin JD, et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. *Nat Med* 2007; **13:** 970–974.
26. Uchida S, De Gaspari P, Kostin S, Jenniches K, Kilic A, Izumiya Y, et al. Sca1-derived cells are a source of myocardial renewal in the murine adult heart. *Stem Cell Rep* 2013; **1:** 397–410.
27. Hsueh YC, Wu JM, Yu CK, Wu KK, Hsieh PC. Prostaglandin E2 promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. *EMBO Mol Med* 2014; **6:** 496–503.
28. Noseda M, Harada M, McSweeney S, Leja T, Belian E, Stuckey DJ, et al. PDGFRα demarcates the cardiogenic clonogenic Sca1$^+$ stem/progenitor cell in adult murine myocardium. *Nat Commun* 2015; **6:** 6930.
29. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. *Proc Natl Acad Sci USA* 2003; **100:** 12313–12318.
30. Holmes C, Stanford WL. Stem cell antigen-1: Expression, function, and enigma (Concise review). *Stem Cells* 2007; **25:** 1339–1347.
31. Matsuura K, Nagai T, Fukushima N, Iwanaga K, Tokunaga M, Shimizu T, et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. *J Clin Invest* 2009; **119:** 2204–2217.
32. Ye J, Boyle A, Shih H, Sievers RE, Zhang Y, Prasad M, et al. Sca-1$^+$ cardiosphere-derived cells are enriched for isl1-expressing cardiac precursors and improve cardiac function after myocardial injury. *PLoS One* 2012; **7:** e30329, doi:10.1371/journal.pone.0030329.
33. Bailey B, Fransioli J, Gude NA, Alvarez R Jr, Zhang X, Gustafsson AB, et al. Sca-1 knockout impairs myocardial and cardiac progenitor cell function. *Circ Res* 2012; **111:** 750–760.
34. Rosenblatt-Velin N, Ogay S, Felley A, Stanford WL, Pedrazzini T. Cardiac dysfunction and impaired compensatory response to pressure overload in mice deficient in stem cell antigen-1. *FASEB J* 2012; **26:** 229–239.
35. Hoch M, Fischer P, Stapel B, Missol-Kolka E, Sekkali B, Scherr M, et al. Erythropoietin preserves the endothelial differentiation potential of cardiac progenitor cells and attenuates heart failure during anti-cancer therapies. *Cell Stem Cell* 2011; **5:** 131–143.
36. Linke A, Muller P, Nurzynska D, Casarsa C, Torella D, Nascimbene A, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. *Proc Natl Acad Sci USA* 2005; **102:** 8966–8971.
37. Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. *Cell* 2013; **154:** 827–842.
38. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *J Exp Med* 1996; **183:** 1797–1806.
39. Matsuzaki Y, Kinjo K, Mulligan RC, Okano H. Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. *Immunity* 2004; **20:** 87–93.
40. Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, Bates S, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. *Dev Biol* 2004; **265:** 262–275.
41. Pfister O, Mouquet F, Jain M, Summer R, Helmes M, Fine A, et al. CD31$^-$ but not CD31$^+$ cardiac side population cells exhibit functional cardiomyogenic differentiation. *Circ Res* 2005; **97:** 52–61.
42. Oyama T, Nagai T, Wada H, Naito AT, Matsuura K, Iwanaga K, et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. *J Cell Biol* 2007; **176:** 329–341.
43. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. *Circ Res* 2004; **95:** 911–921.
44. Cheng K, Ibrahim A, Hensley MT, Shen D, Sun B, Middleton R, et al. Relative roles of CD90 and c-kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. *J Am Heart Assoc* 2014; **3:** e001260, doi:10.1161/JAHA.114.001260.
45. Chong JJ, Chandrakanthan V, Xaymardan M, Asli NS, Li J, Ahmed I, et al. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. *Cell Stem Cell* 2011; **9:** 527–540.
46. Pelekanos RA, Li J, Gongora M, Chandrakanthan V, Scown J, Suhaimi N, et al. Comprehensive transcriptome and immunophenotype analysis of renal and cardiac MSC-like populations supports strong congruence with bone marrow MSC despite maintenance of distinct identities. *Stem Cell Res* 2012; **8:** 58–73.
47. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, et al. The meso-angioblast: A multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. *Development* 2002; **129:** 2773–2783.
48. Galvez BG, Sampaolesi M, Barbuti A, Crespi A, Covarello D, Brunelli S, et al. Cardiac mesoangioblasts are committed, self-renewable progenitors, associated with small vessels of juvenile mouse ventricle. *Cell Death Differ* 2008; **15:** 1417–1428.
49. Galli D, Innocenzi A, Staszewsky L, Zanetta L, Sampaolesi M, Bai A, et al. Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms: A comparison with bone marrow progenitors, fibroblasts, and endothelial cells. *Arterioscler Thromb Vasc Biol* 2005; **25:** 692–697.
50. Lamagna C, Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. *J Leukoc Biol* 2006; **80:** 677–681.
51. Katare R, Riu F, Mitchell K, Gubernator M, Campagnolo P, Cui Y, et al. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. *Circ Res* 2011; **109:** 894–906.
52. Laugwitz KL, Moretti A, Caron L, Nakano A, Chien KR. Islet1 cardiovascular progenitors: A single source for heart lineages? *Development* 2008; **135:** 193–205.
53. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. *Nature* 2004; **432:** 466–472.
54. Smart N, Bollini S, Dube KN, Vieira JM, Zhou B, Davidson S, et al. De novo cardiomyocytes from within the activated adult heart after injury. *Nature* 2011; **474:** 640–644.
55. Dey D, Han L, Bauer M, Sanada F, Oikonomopoulos A, Hosoda T, et al. Dissecting the molecular relationship among various cardiogenic progenitor cells. *Circ Res* 2013; **112:** 1253–1262.
56. Olson EN. Gene regulatory networks in the evolution and development of the heart. *Science* 2006; **313:** 1922–1927.
57. Hidaka K, Shirai M, Lee JK, Wakayama T, Kodama I, Schneider MD, et al. The cellular prion protein identifies bipotential cardiomyogenic progenitors. *Circ Res* 2010; **106:** 111–119.

58. Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. *Cell Stem Cell* 2011; **8:** 228–240.
59. Wamstad JA, Alexander JM, Truty RM, Shrikumar A, Li F, Eilertson KE, et al. Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage. *Cell* 2012; **151:** 206–220.
60. Suter DM, Molina N, Gatfield D, Schneider K, Schibler U, Naef F. Mammalian genes are transcribed with widely different bursting kinetics. *Science* 2011; **332:** 472–474.
61. Chang HH, Hemberg M, Barahona M, Ingber DE, Huang S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. *Nature* 2008; **453:** 544–547.
62. Belian E, Noseda M, Abreu Paiva MS, Leja T, Sampson R, Schneider MD. Forward programming of cardiac stem cells by homogeneous transduction with MYOCD plus TBX5. *PLoS One* 2015 June 5, doi:10.1371/journal.pone.0125384.
63. Tateishi K, Ashihara E, Takehara N, Nomura T, Honsho S, Nakagami T, et al. Clonally amplified cardiac stem cells are regulated by Sca-1 signaling for efficient cardiovascular regeneration. *J Cell Sci* 2007; **120:** 1791–1800.
64. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* 2003; **114:** 763–776.
65. Hong KU, Guo Y, Li QH, Cao P, Al-Maqtari T, Vajravelu BN, et al. c-kit$^+$ cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. *PLoS One* 2014; **9:** e96725, doi:10.1371/journal.pone.0096725.
66. Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. *J Am Coll Cardiol* 2012; **59:** 942–953.
67. Wang X, Hu Q, Nakamura Y, Lee J, Zhang G, From AH, et al. The role of the Sca-1$^+$/CD31$^-$ cardiac progenitor cell population in postinfarction left ventricular remodeling. *Stem Cells* 2006; **24:** 1779–1788.
68. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circ Res* 2010; **106:** 971–980.
69. Malliaras K, Zhang Y, Seinfeld J, Galang G, Tseliou E, Cheng K, et al. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. *EMBO Mol Med* 2013; **5:** 191–209.
70. Liu ML, Nagai T, Tokunaga M, Iwanaga K, Matsuura K, Takahashi T, et al. Anti-inflammatory peptides from cardiac progenitors ameliorate dysfunction after myocardial infarction. *J Am Heart Assoc* 2014; **3:** e001101, doi:10.1161/JAHA.114.001101.
71. Malliaras K, Ibrahim A, Tseliou E, Liu W, Sun B, Middleton RC, et al. Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. *EMBO Mol Med* 2014; **6:** 760–777.
72. Kawaguchi N, Smith AJ, Waring CD, Hasan MK, Miyamoto S, Matsuoka R, et al. c-kitpos GATA-4 high rat cardiac stem cells foster adult cardiomyocyte survival through IGF-1 paracrine signalling. *PLoS One* 2010; **5:** e14297, doi:10.1371/journal.pone.0014297.
73. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. *Cardiovasc Res* 2014; **103:** 530–541.
74. Gray WD, French KM, Ghosh-Choudhary SK, Maxwell JT, Brown ME, Platt MO, et al. Identification of therapeutic covariant microRNA clusters in hypoxia treated cardiac progenitor cell exosomes using systems biology. *Circ Res* 2015; **116:** 255–263.
75. Ibrahim AG, Cheng K, Marban E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. *Stem Cell Rep* 2014; **2:** 606–619.
76. Gyongyosi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. *Circ Res* 2015; **116:** 1346–1360.
77. Marban E. Breakthroughs in cell therapy for heart disease: Focus on cardiosphere-derived cells. *Mayo Clin Proc* 2014; **89:** 850–858.
78. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. *Circulation* 2013; **127:** 213–223.
79. Avolio E, Meloni M, Spencer HL, Riu F, Katare R, Mangialardi G, et al. Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair. *Circ Res* 2015; **116:** e81–e94, doi:10.1161/CIRCRESAHA.1115.306146.
80. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. *Nature* 2007; **445:** 177–182.
81. Chong JJ, Reinecke H, Iwata M, Torok-Storb B, Stempien-Otero A, Murry CE. Progenitor cells identified by PDGFR-alpha expression in the developing and diseased human heart. *Stem Cells Dev* 2013; **22:** 1932–1943.
82. Wu SM, Fujiwara Y, Cibulsky SM, Clapham DE, Lien CL, Schultheiss TM, et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. *Cell* 2006; **127:** 1137–1150.
83. Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, Chen Y, et al. Multipotent embryonic isl1$^+$ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. *Cell* 2006; **127:** 1151–1165.
84. Davis DR, Zhang Y, Smith RR, Cheng K, Terrovitis J, Malliaras K, et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. *PLoS One* 2009; **4:** e7195, doi:10.1371/journal.pone.0007195.
85. Chen WC, Baily JE, Corselli M, Diaz ME, Sun B, Xiang G, et al. Human myocardial pericytes: Multipotent mesodermal precursors exhibiting cardiac specificity. *Stem Cells* 2015; **33:** 557–573.
86. Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, Kroon-Veenboer C, et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. *Cell* 2010; **143:** 134–144.
87. van Berlo JH, Kanisicak O, Maillet M, Vagnozzi RJ, Karch J, Lin SC, et al. c-kit$^+$ cells minimally contribute cardiomyocytes to the heart. *Nature* 2014; **509:** 337–341.
88. Nadal-Ginard B, Ellison GM, Torella D. Response to Molkentin's letter to the editor regarding article, "The absence of evidence is not evidence of absence: The pitfalls of Cre knock-ins in the c-kit locus". *Circ Res* 2014; **115:** e38–e39, doi:10.1161/CIRCRESAHA.115.305380.
89. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. *Cell Stem Cell* 2011; **8:** 389–398.
90. Lee YH, Petkova AP, Konkar AA, Granneman JG. Cellular origins of cold-induced brown adipocytes in adult mice. *FASEB J* 2015; **29:** 286–299.
91. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. *Lancet* 2012; **379:** 895–904.
92. Malliaris K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricULar dySfunction). *J Am Coll Cardiol* 2014; **63:** 110–122.
93. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. *Lancet* 2011; **378:** 1847–1857.
94. Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: Surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. *Circulation* 2012; **126:** S54–S64.
95. Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: The TICAP prospective phase 1 controlled trial. *Circ Res* 2015; **116:** 653–664.
96. Takehara N, Ogata T, Nakata M, Kami D, Nakamura T, Matoba S, et al. The ALCADIA (Autologous Human Cardiac-Derived Stem Cell To Treat Ischemic Cardiomyopathy) trial [abstract]. *Circulation* 2012; **126:** 2776–2799.